Ozanimod in moderate to severe ulcerative colitis

Phase 4, open-label trial of ozanimod in ulcerative colitis (UC) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Percent of Participants Achieving Clinical Response Measured by Modified Mayo Score for Cohort 1 at Week 12 and Percent of Participants Achieving Clinical Response Measured by Modified Mayo Score for Cohort 2 at Week 26. Started Dec 2022; status: terminated.